サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1429586

膵臓がん治療薬の世界市場レポート 2024年

Pancreatic Cancer Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
膵臓がん治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

膵臓がん治療薬の市場規模は、今後数年間で着実に成長すると予想されています。 2028年には4.0%の年間複合成長率（CAGR）で46億5,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、がん罹患率の増加、医療費の急増、政府支援の拡大によるものと考えられます。この期間中に予想される注目すべき動向としては、膵臓がん治療用の新薬開発への集中、新規ナノ医療治療への重点、投資の増加、提携への戦略的焦点、製品革新への取り組みなどが挙げられます。

膵臓がん治療薬市場の予想される成長は、膵臓がんの有病率の増加によって促進されます。膵臓がんの症例数の増加により、医薬品の需要が増加し、その結果、市場の成長が促進されると予想されます。がんの急増は主に、高齢化や肥満に悩む人の増加などの要因に起因しています。たとえば、米国がん協会は、2023年に約6万4,050人（男性3万3,130人、女性3万920人）が膵臓がんの診断を受け、約5万550人（男性2万6,620人、女性2万3,930人）が膵臓がんで亡くなると推定しています。

膵臓がんに焦点を当てた政府の取り組みと資金提供により、膵臓がん治療薬市場のさらなる成長を推進する態勢が整っています。このような政府支援には、公共サービスと経済全体の向上に貢献するプロジェクトやアイデアを持つ選ばれた団体に財政援助を提供することが含まれます。この支援は、膵臓がん患者の生活の質と生存率の向上を目的とした膵臓がん研究にとって特に重要です。一例として、2021年 7月、米国に本拠を置く政府機関である国立がん研究所は、膵臓がんの調査に2億米ドルを割り当てました。したがって、政府の取り組みと資金提供によってもたらされる推進力は、膵臓がん治療薬市場の成長の重要な原動力となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の膵臓がん治療薬市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の膵臓がん治療薬の市場規模実績と成長、2018～2023年
  • 世界の膵臓がん治療薬市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界の膵臓がん治療薬市場、タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 内分泌膵臓がん
  • 外分泌膵臓がん
  • 世界の膵臓がん治療薬市場、薬剤別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • アフィニター
  • エルロチニブ
  • 塩酸塩エベロリムス
  • 5-FU
  • フルオロウラシル
  • ゲムシタニン
  • アブラキサン
  • 世界の膵臓がん治療薬市場、エンドユーザー別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 病院
  • クリニック
  • その他

第7章 地域と国の分析

  • 世界の膵臓がん治療薬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
  • 世界の膵臓がん治療薬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 膵臓がん治療薬市場の競合情勢
  • 膵臓がん治療薬市場の企業プロファイル
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • AstraZeneca PLC
    • F. Hoffmann-La Roche AG
    • Novartis AG

第31章 その他の大手と革新的な企業

  • AbbVie Inc.
  • Merck &Co., Inc.
  • Teva Pharmaceutical Industries
  • Amgen Incorporation
  • Eli Lilly And Company
  • Beigene
  • Chi-Med
  • Cstone Pharmaceuticals
  • Voxtur Bio Ltd
  • Shantu Pharma
  • Krushi Mitra
  • Kremedine Health Private Limited
  • Arlak Biotech
  • Healthkind Labs Pvt. Ltd
  • Swisschem Healthcare Pvt Ltd

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

目次
Product Code: r14557

Pancreatic cancer drugs refer to medications designed for treating pancreatic cancer, a condition resulting from uncontrolled cell growth in the pancreas. This abnormal growth disrupts the pancreas' production of digestive juices and hormones responsible for regulating blood sugar levels. Tissue lumps, known as tumors, develop due to this excessive cell growth, impeding the normal functioning of the pancreas.

Pancreatic cancer drugs can be categorized into two main types endocrine pancreatic cancer and exocrine pancreatic cancer. Exocrine pancreatic cells generate enzymes released into the small intestine to aid in the digestion of food as it traverses the digestive tract. The diverse range of drugs for pancreatic cancer treatment includes Afinitor, erlotinib, hydrochloride everolimus, 5-FU (fluorouracil), gemcitabine, and Abraxane. These drugs find application in various healthcare settings, including hospitals, clinics, and others.

The pancreatic cancer drugs market research report is one of a series of new reports from The Business Research Company that provides pancreatic cancer drugs market statistics, including pancreatic cancer drugs industry global market size, regional shares, competitors with a pancreatic cancer drugs market share, detailed pancreatic cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic cancer drugs industry. This pancreatic cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The pancreatic cancer drugs market size has grown steadily in recent years. It will grow from $3.83 billion in 2023 to $3.98 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The historical period's growth can be attributed to robust economic expansion in emerging markets, a growing aging population, and an increased incidence of pancreatic cancer.

The pancreatic cancer drugs market size is expected to see steady growth in the next few years. It will grow to $4.65 billion in 2028 at a compound annual growth rate (CAGR) of 4.0%. The anticipated growth in the forecast period can be ascribed to an increase in cancer incidence rates, a surge in healthcare expenditure, and growing government support. Notable trends expected during this period include a concentration on the development of new drugs for pancreatic cancer treatment, an emphasis on novel nanomedicine treatment, an increase in investments, a strategic focus on collaborations, and a dedication to product innovations.

The anticipated growth of the pancreatic cancer drugs market is driven by the increasing prevalence of pancreatic cancer. The elevated number of pancreatic cancer cases is expected to boost the demand for drugs, consequently fueling market growth. The surge in cancer instances is largely attributed to factors such as an aging population and a growing number of people dealing with obesity. For example, the American Cancer Society estimates that in 2023, approximately 64,050 individuals (33,130 men and 30,920 women) will receive a pancreatic cancer diagnosis, and about 50,550 people (26,620 men and 23,930 women) will succumb to pancreatic cancer.

Government initiatives and funding focused on pancreatic cancer are poised to drive further growth in the pancreatic cancer drugs market. Such governmental support involves providing financial assistance to selected entities with projects or ideas contributing to the enhancement of public services and the overall economy. This support is particularly crucial for pancreatic cancer research aimed at improving the quality of life and survival rates for patients with this condition. As an illustration, in July 2021, the National Cancer Institute, a US-based government agency, allocated 218.1 million US Dollars for pancreatic cancer research. Therefore, the impetus provided by government initiatives and funding is a significant driver of growth in the pancreatic cancer drugs market.

An ongoing trend in the pancreatic cancer drugs market is the preference for combination therapy over monotherapy. Recognizing the potential to enhance drug efficacy and improve the survival rates of patients with pancreatic cancer, major players in the market are increasingly exploring the combination of two or more drugs. Companies such as Rafael Pharmaceuticals have initiated pivotal Phase 3 trials, such as AVENGER 500, combining CPI-613 (delimitate) with Modified FOLFIRINOX as a first-line treatment for patients with Metastatic Pancreatic Cancer. Apexigen, Inc., a clinical-stage biopharmaceutical company, is also investing in combination therapy, presenting new clinical data on APX005M for patients with metastatic pancreatic cancer.

To gain a competitive edge, major companies in the pancreatic cancer drugs market are investing in local drug delivery systems. This approach involves administering drugs directly to the site of action, enhancing efficacy while minimizing side effects. For instance, OncoLize, a Netherlands-based company, raised a US$ 1.7 million seed investment round in April 2023 to extend their preclinical success with a local drug delivery system for treating pancreatic and lung cancer. This innovative product utilizes unique liquid formulations to deliver a variety of anti-cancer drugs more effectively, both traditional chemotherapy drugs and modern immuno-drugs.

In April 2021, Servier, a France-based pharmaceutical company, acquired Agios Pharmaceuticals for an undisclosed amount. This strategic acquisition strengthens Servier's oncology portfolio, as Agios Pharmaceuticals is a US-based company specializing in drug development, including pancreatic cancer drugs.

Major companies operating in the pancreatic cancer drugs market report are Bristol-Myers Squibb Company, Pfizer Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, Novartis AG, Abbvie Inc., Merck & Co., Inc., Teva Pharmaceutical Industries, Amgen Incorporation, Eli Lilly And Company, Beigene, Chi-Med, Cstone Pharmaceuticals, Voxtur Bio Ltd., Shantu Pharma, Krushi Mitra, Kremedine Health Private Limited, Arlak Biotech, Healthkind Labs Pvt. Ltd., Swisschem Healthcare Pvt Ltd., Apikos Pharma, Kolaz Biotech, Aqvida Gmbh, Baxter International Inc (Uk), Glaxosmithkline PLC, Veropharm, Biocad, Celon Pharma, Celgene Corporation, Johnson & Johnson, Bayer Ag, Eurofarma Laboratorios S.A, Tuteur Argentina, Neopharma Llc, Tabuk Pharmaceuticals, Julphar Life Sciences, Eurolab, Sanofi, Aspen, Zahraa Oncology, Adcock Ingram

North America was the largest region in the pancreatic cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the global pancreatic cancer drugs market share during the forecast period. The regions covered in the pancreatic cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pancreatic cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The pancreatic cancer drugs market consists of sales of Gemcitabine (Gemzar), 5-fluorouracil (5-FU), and Irinotecan (Camptosar). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pancreatic Cancer Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pancreatic cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pancreatic cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pancreatic cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Pancreatic Neuroendocrine Cancer Drugs; Pancreatic Exocrine Cancer Drugs
  • 2) By Drug Combination: Single; Double; Triplet; Quadruplet
  • 3) By End User: Hospital Pharmacies; Retail Pharmacies; Other End-Users
  • Companies Mentioned: Bristol-Myers Squibb Company; Pfizer Inc.; AstraZeneca PLC; F. Hoffmann-La Roche AG; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pancreatic Cancer Drugs Market Characteristics

3. Pancreatic Cancer Drugs Market Trends And Strategies

4. Pancreatic Cancer Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Pancreatic Cancer Drugs Market Size and Growth

  • 5.1. Global Pancreatic Cancer Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Pancreatic Cancer Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Pancreatic Cancer Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Pancreatic Cancer Drugs Market Segmentation

  • 6.1. Global Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Endocrine Pancreatic Cancer
  • Exocrine Pancreatic Cancer
  • 6.2. Global Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Afinitor
  • Erlotinib
  • Hydrochloride Everolimus
  • 5-FU
  • Flurouracil
  • Gemcitanine
  • Abraxane
  • 6.3. Global Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Clinics
  • Other End-Users

7. Pancreatic Cancer Drugs Market Regional And Country Analysis

  • 7.1. Global Pancreatic Cancer Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Pancreatic Cancer Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Pancreatic Cancer Drugs Market

  • 8.1. Asia-Pacific Pancreatic Cancer Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Pancreatic Cancer Drugs Market

  • 9.1. China Pancreatic Cancer Drugs Market Overview
  • 9.2. China Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Pancreatic Cancer Drugs Market

  • 10.1. India Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Pancreatic Cancer Drugs Market

  • 11.1. Japan Pancreatic Cancer Drugs Market Overview
  • 11.2. Japan Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Pancreatic Cancer Drugs Market

  • 12.1. Australia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Pancreatic Cancer Drugs Market

  • 13.1. Indonesia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Pancreatic Cancer Drugs Market

  • 14.1. South Korea Pancreatic Cancer Drugs Market Overview
  • 14.2. South Korea Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Pancreatic Cancer Drugs Market

  • 15.1. Western Europe Pancreatic Cancer Drugs Market Overview
  • 15.2. Western Europe Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Pancreatic Cancer Drugs Market

  • 16.1. UK Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Pancreatic Cancer Drugs Market

  • 17.1. Germany Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Pancreatic Cancer Drugs Market

  • 18.1. France Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Pancreatic Cancer Drugs Market

  • 19.1. Italy Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Pancreatic Cancer Drugs Market

  • 20.1. Spain Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Pancreatic Cancer Drugs Market

  • 21.1. Eastern Europe Pancreatic Cancer Drugs Market Overview
  • 21.2. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Pancreatic Cancer Drugs Market

  • 22.1. Russia Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Pancreatic Cancer Drugs Market

  • 23.1. North America Pancreatic Cancer Drugs Market Overview
  • 23.2. North America Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Pancreatic Cancer Drugs Market

  • 24.1. USA Pancreatic Cancer Drugs Market Overview
  • 24.2. USA Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Pancreatic Cancer Drugs Market

  • 25.1. Canada Pancreatic Cancer Drugs Market Overview
  • 25.2. Canada Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Pancreatic Cancer Drugs Market

  • 26.1. South America Pancreatic Cancer Drugs Market Overview
  • 26.2. South America Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Pancreatic Cancer Drugs Market

  • 27.1. Brazil Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Pancreatic Cancer Drugs Market

  • 28.1. Middle East Pancreatic Cancer Drugs Market Overview
  • 28.2. Middle East Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Pancreatic Cancer Drugs Market

  • 29.1. Africa Pancreatic Cancer Drugs Market Overview
  • 29.2. Africa Pancreatic Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Pancreatic Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Pancreatic Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Pancreatic Cancer Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Pancreatic Cancer Drugs Market Competitive Landscape
  • 30.2. Pancreatic Cancer Drugs Market Company Profiles
    • 30.2.1. Bristol-Myers Squibb Company
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Pfizer Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AstraZeneca PLC
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. F. Hoffmann-La Roche AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Pancreatic Cancer Drugs Market Other Major And Innovative Companies

  • 31.1. AbbVie Inc.
  • 31.2. Merck & Co., Inc.
  • 31.3. Teva Pharmaceutical Industries
  • 31.4. Amgen Incorporation
  • 31.5. Eli Lilly And Company
  • 31.6. Beigene
  • 31.7. Chi-Med
  • 31.8. Cstone Pharmaceuticals
  • 31.9. Voxtur Bio Ltd
  • 31.10. Shantu Pharma
  • 31.11. Krushi Mitra
  • 31.12. Kremedine Health Private Limited
  • 31.13. Arlak Biotech
  • 31.14. Healthkind Labs Pvt. Ltd
  • 31.15. Swisschem Healthcare Pvt Ltd

32. Global Pancreatic Cancer Drugs Market Competitive Benchmarking

33. Global Pancreatic Cancer Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Pancreatic Cancer Drugs Market

35. Pancreatic Cancer Drugs Market Future Outlook and Potential Analysis

  • 35.1 Pancreatic Cancer Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Pancreatic Cancer Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Pancreatic Cancer Drugs Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer